• Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (from parent cell line).
  

PubMed=2653399; DOI=10.1038/bjc.1989.108; PMCID=PMC2247140
Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R.
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Br. J. Cancer 59:527-534(1989)

PubMed=1892748; DOI=10.1038/bjc.1991.279; PMCID=PMC1977519
Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Br. J. Cancer 64:215-220(1991)

PubMed=1423261
Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.
Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Cancer Res. 52:6188-6193(1992)

PubMed=1617660
Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., Harrap K.R.
Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Cancer Res. 52:3857-3864(1992)

PubMed=8795574; DOI=10.1038/bjc.1996.428; PMCID=PMC2074705
Wilson A.P., Dent M.F., Pejovic T., Hubbold L., Radford H.
Characterisation of seven human ovarian tumour cell lines.
Br. J. Cancer 74:722-727(1996)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)